Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Atara Biotherapeutics (ATRA) EBIAT (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of EBIAT readings, the most recent being -$4.1 million for Q1 2026.

  • On a quarterly basis, EBIAT fell 110.91% to -$4.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$9.5 million, a 39.47% increase, with the full-year FY2025 number at $32.7 million, up 138.28% from a year prior.
  • EBIAT hit -$4.1 million in Q1 2026 for Atara Biotherapeutics, down from -$3.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
  • Median EBIAT over the past 5 years was -$21.9 million (2024), compared with a mean of -$33.0 million.
  • Biggest five-year swings in EBIAT: crashed 485.08% in 2023 and later soared 219.71% in 2025.
  • Atara Biotherapeutics' EBIAT stood at -$74.6 million in 2022, then increased by 18.94% to -$60.4 million in 2023, then soared by 79.0% to -$12.7 million in 2024, then soared by 73.17% to -$3.4 million in 2025, then decreased by 21.7% to -$4.1 million in 2026.
  • The last three reported values for EBIAT were -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.3 million (Q3 2025) per Business Quant data.